Topical 5-aminolevulinic acid-mediated photodynamic therapy for basal cell carcinoma

Topical 5-aminolevulinic acid-mediated photodynamic therapy for basal cell carcinoma:



Publication date: Available online 13 February 2020

Source: Photodiagnosis and Photodynamic Therapy

Author(s): E. Filonenko, A. Kaprin, A. Urlova, N. Grigorievykh, V. Ivanova-Radkevich

Abstract

Topical 5-aminolevulinic acid-mediated photodynamic therapy is an established approach for the treatment of basal cell carcinoma. The study with 5- aminolevulinic acid drug Levulon was conducted in patients with superficial skin basal cell carcinoma. The study included 82 patients with overall number of tumor foci of 119. Tumor sites were as follows: head and neck, trunk, extremities. A photodynamic therapy session was performed using a laser with a wavelength of 630 nm, an energy density of 350 J/cm². A complete response was recorded in 77 patients (114 foci) with an excellent cosmetic result. According to the analysis of survival in the group of patients with a complete response, the overall RFS was as follows: 1-year rate – 92.1%, 3-year – 88.3%. Photodynamic therapy with topical Levulon in patients with superficial BCC of the skin was effective and safe.